Skip to content
‹ Back to IndustriesHealthcare

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Elizabeth Venafro · Revenue Cycle ManagementClaim DenialsUnderpaymentsContract Verification
Share

Key takeaways

01

Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.

02

The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.

03

Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A denied claim gets a queue. Someone owns it, someone works it, and it stays visible until it's resolved. A paid claim that came in lower than expected gets none of that. It posts, and the day moves on.

That gap is the subject of RSK's clip "Why Underpayments Are Hard to Spot." The speaker argues that most revenue cycle operations are built to catch a no, and an underpayment isn't a no. "This was a yes," the speaker says. "It was just smaller yes, and a smaller yes looks like a normal day."

For a revenue cycle lead, the question is simple to ask and harder to answer: if the workflow only kicks in when a payer says no, who checks the payments that went through?

Why the smaller yes is getting harder to see

The speaker points to pressure from both sides of the claim. Contracts have gotten more complex. Payer systems have gotten more automated, and in the speaker's view, payers are using AI "to find more ways to hold on to their cash."

On the provider side, the speaker says provider groups "have never really been armed with the contract intelligence at the line level." So the mismatch runs like this: the terms that decide what a claim should pay keep getting more detailed, while the people receiving the payment often can't check each line against those terms.

These are the speaker's characterizations, and the clip doesn't attach measurements to them. The workflow logic holds either way. A denial workflow starts with an event: the rejection. An underpayment produces no event. The money arrives, and nothing in a queue-based process flags it as work.

Checking paid claims against the payer is really a back end of the revenue cycle, and it's the one part almost nobody thoroughly owns. — Speaker, RSK's "Why Underpayments Are Hard to Spot"

Payment received and payment checked are different steps

Handling a denial and verifying a paid claim answer different questions. The first asks whether the payer accepted the claim. The second asks whether the payment matches what the applicable terms require. Most operations have a clear owner for the first. The speaker's point is that the second often has no owner at all.

This is a question about the scope of payment review, not a finding that every smaller payment is wrong. Establishing an underpayment requires determining what was owed under the relevant terms and comparing that with the actual payment.

That's why the clip keeps coming back to line level. The contract terms apply line by line, so any check that stops at "was it paid" answers a narrower question than "was it paid correctly." A team can clear every denial in its queue and still never look at the second question.

Start with who owns it

The clip asks teams to look harder at who is responsible for the work after payment arrives. Before choosing any tool or process, someone has to decide that a paid claim isn't closed until it has been checked against what the contract says.

Ask who on your team compares paid claims, line by line, to the applicable contract terms, and what triggers that review. If the answer is nobody, or only when something looks off, smaller payments are being treated as finished work.

A denial gets attention because it shows up in a queue. A smaller yes doesn't, so someone has to be assigned to go looking for it.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

A clean, paid, closed claim can still be short of the contract

A clean, paid, closed claim can still be short of the contract

Practices can receive payment on closed, clean claims that still fall short of negotiated contract amounts because billing ends at coding, submission and posting, while no role owns checking whether payer payments match fee schedules. The speaker argues that contract-level payment review is a separate, complementary function that compares closed claims to contract terms and, run continuously, helps surface shortfalls in time to act within timely filing windows.

  • 01Correctly coded and billed healthcare claims can still result in underpayment.
  • 02Practices should review closed-claim payments against contract terms to spot underpayments.
  • 03Discrepancies in claim payments can persist despite adherence to billing protocols.

Nov 6, 2026

Moderna swings to a profit and raises its 2026 revenue outlook as newer vaccines gain traction

Moderna swings to a profit and raises its 2026 revenue outlook as newer vaccines gain traction

Moderna reported third-quarter revenue of $1.31 billion, up 29%, and net income of $162 million, compared with a $200 million loss a year earlier. International COVID vaccine sales under long-term government partnerships and the full-year impact of its next-generation COVID vaccine drove growth, while lower costs helped the profit. The company raised its 2026 revenue growth outlook to 15% to 25% from up to 10%. Its flu shot, mFLUSIVA, was approved in the U.S. and will have a limited U.S. launch in 2026.

  • 01Third-quarter revenue rose 29% to $1.31 billion, with $780 million in the U.S. and $533 million internationally.
  • 02Net income was $162 million, or 38 cents per share, versus a $200 million loss a year earlier.
  • 03Moderna now expects 2026 revenue growth of 15% to 25%, up from up to 10%.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

EV
Elizabeth Venafro

Fractional CMO

RSK

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512